Xuebin Qu

Prof. Dr. Xuebin Qu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2025 in Neurochemistry International
Verified
Journal Article
Closed access
JHJingjing Han
Jingjing Han
RHRui Hong
Rui Hong
CCCong Cao
Cong Cao
LZLina Zhang
Lina Zhang
ASAo Sun
Ao Sun
XQXuebin Qu
Xuebin Qu

3 February 2024 in Biochemistry and Molecular Biology Education
Verified
Journal Article
Closed access
JHJingjing Han
Jingjing Han
LZLina Zhang
Lina Zhang
LYLiucai Yang
Liucai Yang
YLYougen Luo
Yougen Luo
RYRuiqin Yao
Ruiqin Yao
XQXuebin Qu
Xuebin Qu

24 December 2024 in Biochemistry and Molecular Biology Education
Verified
Journal Article
Closed access
LYLiucai Yang
Liucai Yang
YYYa Yang
Ya Yang
YZYingling Zhu
Yingling Zhu
HZHu Zhang
Hu Zhang
FTFeixiang Teng
Feixiang Teng
XQXuebin Qu
Xuebin Qu

15 April 2025 in Advanced Science
Verified
Journal Article
Open access
JHJingjing Han
Jingjing Han
RHRui Hong
Rui Hong
CCCong Cao
Cong Cao
WFWanhua Feng
Wanhua Feng
WZWei Zhuang
Wei Zhuang
XQXuebin Qu
Xuebin Qu
The damage of blood spinal cord barrier (BSCB) is contributing to the disruption of immune microenvironment within central nervous system during the progression of multiple sclerosis (MS) and experimental allergic encephalomyelitis (EAE). Nevertheless, the underlying mechanisms responsible for barrier impairment remain inadequately understood. Here, by analyzing the protein profiles in peripheral blood serum, chemokine (C‐X‐C motif) ligand 13 (CXCL13) was identified to be increased with the progression of MS and EAE. The absence of CXCL13 resulted in alleviation of EAE symptoms, as evidenced by a reduced clinical score, decreased barrier damage, as well as diminished demyelination and inflammatory response in the spinal cord. In the BSCB model, CXCL13 was found to impair barrier structure and function in a dose‐ and time‐dependent manner, which was associated with exacerbated autophagy in endothelial cells, while the application of autophagy inhibitors partially mitigated this damage. Mechanistically, CXCL13 enhanced the expression of RNF6, an E3 ubiquitin‐protein ligase, facilitating the conjugation to Sqstm1 for the ubiquitination at the K314 residue. These findings suggest that CXCL13 significantly contributes to the impairment of the BSCB by promoting RNF6/Sqstm1‐ubiquitination‐induced autophagy during the progression of EAE, thereby offering a promising diagnostic and therapeutic target for MS.

15 May 2025 in BMC Psychiatry
Verified
Journal Article
Open access
CCCong Cao
Cong Cao
XXXuehao Xu
Xuehao Xu
SSSumei Shen
Sumei Shen
XBXiyan Bao
Xiyan Bao
FWFenglan Wang
Fenglan Wang
AZAihua Zhou
Aihua Zhou
Clinically stable inpatients with schizophrenia have generalized impairment of cognitive function along with abnormalities in renal function, but the link between cognitive function and renal function has been underexplored. This study enrolled 216 hospitalized patients with clinically stable schizophrenia. Demographic and renal function parameters were collected from electronic medical records. Cognitive function was assessed using the Chinese Brief Cognitive Test (C-BCT). To analyze the correlations between renal function and processing speed, attention, working memory, and executive function in patients hospitalized with clinically stable schizophrenia. Covariate-adjusted linear and multivariate logistic regression models were constructed to determine the relationship between renal function and cognitive function. ROC analysis was used to further investigate the prediction of renal function indices in assessing stable schizophrenia inpatients. Significant variations in serum Cystatin C (CysC), β2-microglobulin (β2-MG), and uric acid (UA) levels were observed among hospitalized patients with clinically stable schizophrenia across different cognitive impairment severities. Correlation analysis revealed a significant association between serum CysC levels and C-BCT scores in hospitalized patients with stable schizophrenia (β = 0.174, 95%CI:0.265 ~ 1.720, p = 0.008). Particularly strong correlations were observed with processing speed T-scores (β = -0.200, 95%CI: -33.446 ~ -7.230, p = 0.03) and executive function T-scores (β = -0.171, 95%CI: -17.277 ~ -2.082, p = 0.013). Binary logistic regression analysis further confirmed that CysC may be a risk factor for exacerbation of cognitive impairment in stable schizophrenia (OR = 12.741, 95%CI: 1.424 ~ 114.005, p = 0.023). The combined serum CysC, β2-MG, and UA test for cognitive function in stable schizophrenia inpatients had an AUC area of 0.71, with a sensitivity and specificity of 79.5% and 60.5%, respectively, and a predictive value superior to that of an independent diagnosis. In hospitalized patients with stable schizophrenia, serum CysC levels are positively correlated with the severity of cognitive impairment, particularly showing significant associations with information processing speed and executive function. CysC may be a risk factor for exacerbating cognitive impairment in these patients. The combined diagnostic value of serum CysC, β2-MG, and UA demonstrated moderate accuracy in identifying stable schizophrenia cognitive impairment. These data support the potential of CysC as a biomarker of cognitive function in stable schizophrenia.

8 December 2025 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
TSTong Shen
Tong Shen
CCCan Cui
Can Cui
RLRuiqi Liu
Ruiqi Liu
XYXin Yin
Xin Yin
JZJie Zu
Jie Zu
CZChu Zhang
Chu Zhang
Cognitive impairment (CI) is a common and early non-motor manifestation of Parkinson’s disease (PD), yet its biochemical basis remains poorly understood. Given the emerging link between bile acids (BAs) and neurodegeneration, we investigated whether serum BA profiles differ by cognitive status in PD and whether they can classify CI. A total of 363 participants were enrolled, including 63 healthy controls, 154 PD patients with normal cognition, and 146 with CI. Serum BA concentrations were quantified by ultra-performance liquid chromatography–tandem mass spectrometry, and multivariate as well as machine learning analyses were applied. Compared with cognitively normal PD patients, those with CI exhibited distinct BA alterations, characterized by elevated deoxycholic and cholic acids and reduced glyco- and tauro-conjugated species. Deoxycholic acid showed the strongest negative correlations with cognitive scores. Machine learning models based on combined BA profiles, particularly the random forest classifier, achieved robust discrimination between PD-CI and PD-NC groups (AUC up to 0.90). These findings indicate that BA dysregulation is closely linked to cognitive impairment in PD and may serve as a promising metabolic biomarker for early detection. Clinical trial number. Not applicable.